Free shipping on all orders over $ 500

IDH-305

Cat. No. M10335
IDH-305 Structure
Synonym:

IDH305

Size Price Availability Quantity
10mg USD 220  USD220 In stock
25mg USD 450  USD450 In stock
50mg USD 680  USD680 In stock
100mg USD 1100  USD1100 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

IDH-305 is an orally available, mutant-selective and brain-penetrant IDH1 inhibitor that targets IDH1(R132) mutation with IC50 values of 27 nM, 28 nM and 6.14 μM for IDH1R132H, IDH1R132C and IDH1WT, respectively.

In vivo, IDH-305 (30-300 mg/kg; p.o.; twice daily for 21 days) inhibits 2-HG production and 2-HG-dependent tumor growth of an IDH1 mutant PDX melanoma model.

Chemical Information
Molecular Weight 490.45
Formula C23H22F4N6O2
CAS Number 1628805-46-8
Solubility (25°C) DMSO 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Juan Eduardo Megias-Vericat, et al. Blood Lymphat Cancer. IDH1-mutated relapsed or refractory AML: current challenges and future prospects

[2] Young Shin Cho, et al. ACS Med Chem Lett. Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor

[3] Takeo Fujii, et al. Discov Med. Targeting isocitrate dehydrogenase (IDH) in cancer

Related Isocitrate Dehydrogenase (IDH) Products
Mutant IDH1-IN-4

Mutant IDH1-IN-4 is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH 1) with an IC50 value of ≤ 0.5 μM for mutant IDH 1 in R132H, HT1080 and U87R132H cells.

(S,S)-GSK321

(S,S)-GSK321 is the (S,S)-enantiomer of GSK321.GSK321 is a potent inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme.

IDH1 Inhibitor 1

IDH1 Inhibitor 1 is a potent, orally bioavailable, brain-permeable, selective mutant IDH1 inhibitor that inhibits IDH1R132H, IDH1R132C, and IDH1WT with IC50s of 0.021 μM, 0.045 μM, and 2.52 μM, respectively. possesses antitumor activity.

IDH1 Inhibitor 7

IDH1 Inhibitor 7 is an IDH1 inhibitor with an IC50 of less than 100 nM.

(R,R)-GSK321

(R,R)-GSK321 is an isomer of GSK321 and a wild-type isocitrate dehydrogenase 1 (WT IDH1) inhibitor with an IC50 value of 120 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: IDH-305, IDH305 supplier, Isocitrate Dehydrogenase (IDH), inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.